Navigation Links
Are women opting out or shut out from career tracks?

s to 28 percent.

The most troubling statistic from the survey only 5 percent of highly qualified women looking for on-ramps back into the career mainstream are interested in rejoining the organizations they left. It was zero for respondents working in the business sector! The authors surmise that these women felt they were not appreciated or well-utilized by their previous employers.
......

Full article >>>
'"/>

Source:wistechnology.com By Tony DiRomualdo 04/25/05


Page: 1 2 3 4

Related biology technology :

1. Research explains why women lack equal access to angel capital
2. Learning from the big boys: With technology, women urged to go gradual
3. MATC seeks to turn around falling tech enrollment among women
4. More women needed in interface design
5. GE introduces compact ultrasound system for women
6. Angel fund to focus on women and minority businesses
7. Despite gains, women still face bias in science careers
8. Biotech executive books a career flight thats closer to home
9. UW engineering career fair sees highest attendance in four years
10. Local focus brings national success for Wisconsin career site
11. Manufacturing still viable career
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Are women opting out shut out from career tracks

Breaking Biology News(10 mins):MSU researcher unveils new approach to treat lower back pain 2Leibniz Prize 2010: 10 winners receive honor, prize money and 'idyllic freedom' 2Leibniz Prize 2010: 10 winners receive honor, prize money and 'idyllic freedom' 3Leibniz Prize 2010: 10 winners receive honor, prize money and 'idyllic freedom' 4Leibniz Prize 2010: 10 winners receive honor, prize money and 'idyllic freedom' 5Leibniz Prize 2010: 10 winners receive honor, prize money and 'idyllic freedom' 6Leibniz Prize 2010: 10 winners receive honor, prize money and 'idyllic freedom' 7Leibniz Prize 2010: 10 winners receive honor, prize money and 'idyllic freedom' 8Leibniz Prize 2010: 10 winners receive honor, prize money and 'idyllic freedom' 9Leibniz Prize 2010: 10 winners receive honor, prize money and 'idyllic freedom' 10Plate-eating good: Université de Montréal professor designs edible tableware 2Lexicon Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Unplugged Conference 13924 1Lexicon Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Unplugged Conference 13924 2VIVUS Announces Positive Results From Two Phase 3 Studies 3B Obese Patients on Qnexa Achieve Average Weight Loss up to 14 7 25 and Significant Improve 13923 1VIVUS Announces Positive Results From Two Phase 3 Studies 3B Obese Patients on Qnexa Achieve Average Weight Loss up to 14 7 25 and Significant Improve 13923 2VIVUS Announces Positive Results From Two Phase 3 Studies 3B Obese Patients on Qnexa Achieve Average Weight Loss up to 14 7 25 and Significant Improve 13923 3VIVUS Announces Positive Results From Two Phase 3 Studies 3B Obese Patients on Qnexa Achieve Average Weight Loss up to 14 7 25 and Significant Improve 13923 4VIVUS Announces Positive Results From Two Phase 3 Studies 3B Obese Patients on Qnexa Achieve Average Weight Loss up to 14 7 25 and Significant Improve 13923 5VIVUS Announces Positive Results From Two Phase 3 Studies 3B Obese Patients on Qnexa Achieve Average Weight Loss up to 14 7 25 and Significant Improve 13923 6VIVUS Announces Positive Results From Two Phase 3 Studies 3B Obese Patients on Qnexa Achieve Average Weight Loss up to 14 7 25 and Significant Improve 13923 7VIVUS Announces Positive Results From Two Phase 3 Studies 3B Obese Patients on Qnexa Achieve Average Weight Loss up to 14 7 25 and Significant Improve 13923 8VIVUS Announces Positive Results From Two Phase 3 Studies 3B Obese Patients on Qnexa Achieve Average Weight Loss up to 14 7 25 and Significant Improve 13923 9New Chief Executive Officer and Vice President Commercial Operations USA at the Helsinn Groups American subsidiary Helsinn Therapeutics 28U S 29 In 56516 1New Chief Executive Officer and Vice President Commercial Operations USA at the Helsinn Groups American subsidiary Helsinn Therapeutics 28U S 29 In 56516 2